

STIC-Biotech/ChemLib

148385

From: Unknown@Unknown.com
Sent: Monday, March 21, 2005 3:39 PM
To: STIC-Biotech/ChemLib
Subject: Generic form response

ResponseHeader=Commercial Database Search Request

AccessDB#= _____

LogNumber= _____

Searcher= _____

SearcherPhone= _____

SearcherBranch= _____

MyDate=Mon Mar 21 15:37:52 EST 2005

submitto=Biotech01@uspto.gov

Name=Ray Henley

Empno=66553

Phone=x20575

Artunit=1614

Office=REM3A69

Serialnum=09/585,431

PatClass=514/274

Earliest=January 3, 1991

Format1=paper

Searchtopic=Could you please do a litigation search for

U.S. Patent No. 5,532,246, issued July 2, 1996 to
Bernard Belleau, deceased, et al.

Thanks,

Ray

Comments=

send=SEND

STAFF USE ONLY

Searcher: _____
Searcher Phone: 2- _____
Date Searcher Picked up: _____
Date Completed: _____
Searcher Prep/Rev. Time: _____
Online Time: _____

Type of Search

NA#: _____ AA#: _____
Interference: _____ SPDI: _____
S/L: _____ Oligomer: _____
Encode/Transl: _____
Structure#: _____ Text: _____
Inventor: _____ Litigation: _____

Vendors and cost where applicable

STN: _____
DIALOG: _____
QUESTEL/ORBIT: _____
LEXIS/NEXIS: _____
SEQUENCE SYSTEM: _____
WWW/Internet: _____
Other(Specify): _____

QUESTEL - Time in minutes : 2,59

Selected file: PLUSPAT

PLUSPAT - (c) Questel-Orbit, All Rights Reserved.
 Comprehensive Worldwide Patents database
 New Patent Citation Commands & FAM Citation Report - see INFO PATCITE
 Announcing enhanced searchability of Relevancy Codes in Search Reports
 for EP, WO and FR patents. For more details see below and on QO website
 -To retrieve set of high relevancy X coded cited patents, use xctx=yes
 -To extract cited patents with only high relevancy code, use mem/xctx
 Last update of file: 2005/03/23 (YYYY/MM/DD) 2005-11/UP (last update)

Search statement 1

?us5532246/pn

** SS 1: Results 1

Search statement 2

?prt full legalall max

1/1 PLUSPAT - (C) QUESTEL-ORBIT
 PN - US5532246 A 19960702 [US5532246]
 TI - (A) Use of 1,3-oxathiolane nucleoside analogues in the treatment of
 hepatitis B
 PA - (A) IAF BIOCHEM INT (CA)
 PA0 - BioChem Pharma, Inc., Laval [CA]
 IN - (A) BELLEAU BERNARD (CA); NGUYEN-BA NGHE (CA)
 AP - US8422293 19930809 [1993US-0084222]
 FD - PCT/CA92/00001 19920103 [1992WO-CA00001]
 - WO92/11852 19920723 [WO9211852]
 PR - WOCA9200001 19920103 [1992WO-CA00001]
 - GB9100039 19910103 [1991GB-0000039]
 - GB9109913 19910507 [1991GB-0009913]
 IC - (A) A61K-031/505
 EC - A61K-031/505
 - A61K-031/70C
 PCL - ORIGINAL (O) : 514274000
 DT - Corresponding document
 CT - US5039667; US5047407; EP0206497 A2; EP0302760 B; EP0349242 A2;
 EP0382526 A2; EP0421739 A1; EP0421777 A1; EP0421819 A1; EP0505181 A1;
 EP0515144 A1; GB2230266; WO8904662; WO9012023; WO9216215; WO9014079;
 WO9014091; WO9100282; WO9101137; WO9101326; WO9111186; WO9117159;
 WO9208717; WO9214743; WO9215308; WO9218517; WO9219246
 - Beach et al., "Synthesis of Enantiomerically Pure (2'R,5'S)-(-)-1-
 2-(Hydroxymethyl) oxathiolan-5-ylcytosine as a Potent Antiviral Agent
 Against Hepatitis B Virus (HBV) And Human Immunodeficiency Virus
 (HIV)," 57 J. Org. Chem., pp. 2217-2219 (1992).

Belleau et al., "Design And Activity Of A Novel Class Of Nucleoside
 Analogs Effective Against HIV-1," Fifth International Conference On
 AIDS, Montreal, Canada, Abstract T.C.O.1 (1989).

Carlisle et al., "Cellular Pharmacology Of The Anti-HIV Agent BCH-189
 (2'-Deoxy-3'-Thiacytidine) In Human Peripheral Blood Mononuclear Cells
 (PBMC)", American Association For Cancer Research Proceedings, 31
 Abstract 2435 (1990).

- Chang et al., "Deoxycytidine Deaminase-resistant Stereoisomer Is the Active Form of (\pm)-2',-3'-Dideoxy-3'-thiacytidine in the Inhibition of the Hepatitis B Virus Replication," 267 J. Biol. Chem., pp. 3938-3942 (1992).
- Coates et al., "The Separated Enantiomers of 2'-Deoxy-3'-Thiacytidine (BCH 189) Both Inhibit Human Immunodeficiency Virus Replication in Vitro," 36 Antimicrobial Agents & Chemotherapy, No. 1, pp. 202-205 (1992).
- Doong et al., "Inhibition of the Replication of Hepatitis B Virus In-Vitro By 2'3' Dideoxy-3'-thiacytidine and Related Analogues," Thirty-first Annual Interscience Conference of Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 29 Sep.-2 Oct. 1991, Program Abstract 31(0) 181 (1991).
- Doong et al., "Inhibition of the Replication of Hepatitis B Virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues," 88 Proc. Natl. Acad. Sci., USA, pp. 8495-8499; 88 Physiology/Pharmacology 8495-8499 (1991).
- Greenberg et al., "Metabolism, Toxicity, and Anti-HIV Activity of 2'-Deoxy-3'-Thia-Cytidine (BCH-189) in T and B Cell Lines," 616 Annals of the New York Academy Of Sciences 517-518 (1990).
- Kassianides et al. Abstract: "Effects of 2',3'-dideoxycytidine on Duck Hepatitis B Virus," 94 Gastroenterology No. 5, A552 (1988).
- Kassianides et al., "Inhibition of Duck Hepatitis B Virus Replication by 2',3'-Dideoxycytidine," 97 Gastroenterology, No. 5, 1275-1280 (1989).
- Lee et al., "In Vitro and In Vivo Comparisons of the Abilities of Purine and Pyrimidine 2',3'-Dideoxynucleosides To Inhibit Duck Hepadnavirus," 33 Antimicrobial Agents and Chemotherapy, No. 3, 336-39 (1989).
- Soudeyns et al., "Anti-Human Immunodeficiency Virus Type 1 Activity and In Vitro Toxicity of 2'-Deoxy-3'-Thiacytidine (BCH-189), a Novel Heterocyclic Nucleoside Analog," 35 Antimicrobial Agents and Chemotherapy, No. 7, pp. 1386-1390 (1991).
- Suzuki et al., "Inhibition of Hepatitis B Virus Replication By Purine 2',3'-Dideoxynucleosides," 156 Biochemical and Biophysical Research Communications 1144-1151 (1988).
- Wainberg et al., Abstract, "Anti-HIV-1 Activity, Toxicity And Pharmacokinetics of Totally Novel Nucleoside Analogs," M.C.P.63, V International Conference on AIDS, Montreal, Quebec, Canada, Jun. 4-9, 1989.
- Wainberg et al., "Characterization Of AZT-Resistant Isolates Of HIV-1: Susceptibility To Deoxythiacytidine And Other Nucleosides," VI International Conference On AIDS, San Francisco, California, vol. 3, Abstract S.B.87, p. 117 (1990).
- Sandstrom et al., "Antiviral Therapy in AIDS: Clinical Pharmacological Properties and Therapeutic Experience to Date," 34 Drugs, pp. 372-390

(1987).

Varmus, "A Growing Role For Reverse Transcription," 299 Nature, pp. 204-205 (1982).

STG - (A) United States patent

AB - PCT No. PCT/CA92/00001 Sec. 371 Date Aug. 9, 1993 Sec. 102(e) Date Aug. 9, 1993 PCT Filed Jan. 3, 1992 PCT Pub. No. WO92/11852 PCT Pub. Date Jul. 23, 1992. Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of hepatitis B is disclosed. <IMAGE> (I)

1/1 LGST - (C) EPO

PN - US5532246 A 19960702 [US5532246]

AP - US8422293 19930809 [1993US-0084222]

ACT - 19940706 US/AS02-A

ASSIGNMENT OF ASSIGNOR'S INTEREST

OWNER: BIOCHEM PHARMA, INC. 275 ARMAND FRAPPIER BLVD. LAV; EFFECTIVE DATE: 19930623

- 19940706 US/AS02-A

ASSIGNMENT OF ASSIGNOR'S INTEREST

OWNER: BELLEAU, BERNARD; EFFECTIVE DATE: 19930623

- 19940706 US/AS02-A

ASSIGNMENT OF ASSIGNOR'S INTEREST

OWNER: NGUYEN-BA, NGHE; EFFECTIVE DATE: 19930623

- 19970204 US/CC-A

CERTIFICATE OF CORRECTION

- 20000725 US/RF-A

REISSUE APPLICATION FILED

EFFECTIVE DATE: 20000602

UP - 2003-22

1/1 CRXX - (C) CLAIMS/RRX

AN - 2735443

PN - 5,532,246 A 19960702 [US5532246]

PA - BioChem Pharma Inc CA

PT - C (Chemical)

ACT - 20000602 REISSUE REQUESTED

Issue Date of O.G.: 20000725

Reissue Request Number: 09/585431

Examination Group responsible for Reissue process: 1614

UP - 2000-30

UACT- 2000-07-25

□Search statement 2

?st

Session finished: 23 MAR 2005 Time 15:03:17

PLUSPAT - Time in minutes : 0,82

The cost estimation below is based on Questel's standard price list

Estimated cost : 2.25 USD